Skip to main content
. Author manuscript; available in PMC: 2024 Jul 1.
Published in final edited form as: J Pathol. 2023 May 31;260(3):353–364. doi: 10.1002/path.6087

Figure 3. Sparsentan delayed the decline in GFR and renal pathology in aged AS mice.

Figure 3.

GFR and renal pathology in WT and AS mice treated with vehicle or sparsentan from 4 wk of age. (A) Comparison of GFR at 9 wk of age. ***P<0.001, ****P<0.0001, WT-V (n=6) or AS-SP (n=15) compared to AS-V mice (n=10). Preservation of GFR in AS-SP mice compared to AS-V mice was associated with amelioration at 10 wk of age of (B) GS and (C) TIF. **P<0.01 AS-SP (n=7) compared to AS-V (n=4). (D) Representative sections from three WT-V, AS-V, and AS-SP mice following staining with an anti-COLI antibody, indicating the attenuation of fibrosis in 10-wk-old AS-SP mice. Data in panel A are shown as their median; data in B and C are shown as their mean±SD. Analysis of panel A data used 1-way ANOVA followed by Tukey’s multiple comparison test. Analysis of panels B and C data was conducted using a 2-tailed Student’s t test. All analyses were performed using GraphPad Prism.